Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Palisade Bio (PALI) EBITDA (2016 - 2025)

Palisade Bio (PALI) has disclosed EBITDA for 16 consecutive years, with -$2.9 million as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA rose 18.68% to -$2.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$11.5 million, a 21.69% increase, with the full-year FY2024 number at -$14.9 million, down 13.69% from a year prior.
  • EBITDA was -$2.9 million for Q3 2025 at Palisade Bio, down from -$2.8 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$2.3 million in Q1 2021 to a low of -$4.4 million in Q3 2022.
  • A 5-year average of -$3.4 million and a median of -$3.6 million in 2022 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: skyrocketed 69.81% in 2021, then crashed 70.0% in 2022.
  • Palisade Bio's EBITDA stood at -$2.3 million in 2021, then crashed by 68.25% to -$3.8 million in 2022, then increased by 18.04% to -$3.2 million in 2023, then fell by 7.23% to -$3.4 million in 2024, then rose by 13.6% to -$2.9 million in 2025.
  • Per Business Quant, the three most recent readings for PALI's EBITDA are -$2.9 million (Q3 2025), -$2.8 million (Q2 2025), and -$2.3 million (Q1 2025).